Osteoarthritis journal

Crowley DC, Lau FC, Sharma P, Evans Osteoarthritis journal, Guthrie N, Bagchi M, Bagchi D, Dey DK, Raychaudhuri SP. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. C treated group after 90 days.

90 days as compared to 15. The Lequesne’s functional index was used to determine the effect of different treatments on pain during daily activities. C treated group at the end of 90-day treatment. Thus, UC-II treated subjects showed significant enhancement in daily activities suggesting an improvement in their quality of life. Arthritis afflicts approximately 43 million Americans or approximately 16.

Other symptoms include morning stiffness and gelling of the involved joint after periods of inactivity. 60 years thus compromising the quality of life of millions of Americans. The most common medications include acetaminophen and NSAIDs. Although these drugs are effective for reducing pain associated with OA, they do not reverse the disease. In addition, there are considerable side effects associated with the use of these drugs.

As a result, OA sufferers have turned to natural nutraceuticals to ease their pain and discomfort. These products are commonly used because they are well tolerated and considered safe. Nutraceuticals are defined as functional foods, natural products, or parts of food that provide medicinal, therapeutic, or health benefits, including the prevention or treatment of disease. An emerging novel nutraceutical ingredient known as UC-II has received considerable attention in the treatment of OA. UC-II is a novel undenatured type II collagen derived from chicken sternum cartilage.

Greater improvement was observed with the 40 mg dose. No adverse effects or significant changes in serum chemistry were noted. Following UC-II withdrawal for a period of 30 days, all dogs experienced a relapse of overall pain, exercise-associated lameness and pain upon limb manipulation. The present clinical trial evaluated the safety and efficacy of UC-II in the treatment of the knee in OA patients.

The VAS score, the WOMAC Index and Lequesne scores were obtained. Urine was collected for a pregnancy test for women of childbearing potential. Upon review of blood test results, eligible subjects were instructed to get an X-ray of the affected knees to confirm diagnosis. The clinical assessments included WOMAC, Lequesne’s functional index and 100-mm VAS pain scores. A subject treatment diary was completed by each patient throughout the study period to determine side effects, medication use, and product compliance. The study was a two-site, randomized, double-blind study conducted in London, Ontario and Corunna, Ontario, Canada.

Click on the image to enlarge. Blood sample: ALT, AST, bilirubin, albumin. Moderate OA as indicated by Lequesne’s functional index score of 4. Recent injury in the area affected by OA of the knee, i. 20 mg UC-II standardized to 5 mg of bioactive undenatured type II collagen.